Antihypertensive

RegulatoryAugust 6, 2026

Teva's Losartan Potassium Supplement Application Receives Standard Review Status

Teva's ANDA for Losartan Potassium has been submitted and is currently under standard review by the FDA.

RegulatoryAugust 2, 2026

FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094

The FDA has approved QLONILIK, containing Clonidine Hydrochloride, under NDA221094.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for AVAPRO by Sanofi

The FDA has accepted a supplemental application for AVAPRO (irbesartan) from Sanofi.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental NDA for AVAPRO by Sanofi

The FDA has accepted a supplemental NDA for AVAPRO, indicating ongoing development and potential label expansion.

RegulatoryJuly 29, 2026

FDA Approval Status for Valsartan and Hydrochlorothiazide by Sciegen Pharms

The FDA has granted approval status (AP) for ANDA204687, a combination of Valsartan and Hydrochlorothiazide by Sciegen Pharms.

StrategyJuly 28, 2026

FDA Grants Approval for Valsartan ANDA218897 by Laurus

The FDA has granted approval for ANDA218897, a generic version of Valsartan, submitted by Laurus.

RegulatoryJuly 26, 2026

FDA Approval Process for Olmesartan Medoxomil and Hydrochlorothiazide by Micro Labs

The FDA has received an application for Olmesartan Medoxomil and Hydrochlorothiazide from Micro Labs, currently under standard review.

StrategyJuly 18, 2026

FDA Grants Approval for Irbesartan ANDA077205 by Chartwell Molecular

The FDA has granted approval for ANDA077205, a supplemental application for Irbesartan submitted by Chartwell Molecular.

RegulatoryJuly 18, 2026

FDA Grants AP Status for Irbesartan ANDA206194 by Hisun Pharm

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Irbesartan submitted by Hisun Pharm.

RegulatoryJuly 13, 2026

Crescent Pharma recalls Ramipril 2.5mg due to packaging error

Crescent Pharma Limited is recalling Ramipril 2.5mg capsules due to a packaging error that may lead to patients receiving the incorrect dosage.

StrategyJuly 5, 2026

FDA Grants AP Status for Olmesartan Medoxomil and Hydrochlorothiazide ANDA207037

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Olmesartan Medoxomil and Hydrochlorothiazide submitted by Alkem Labs.

StrategyJuly 5, 2026

FDA Approves ANDA204687 for Valsartan and Hydrochlorothiazide

The FDA has approved ANDA204687, a generic formulation of Valsartan and Hydrochlorothiazide, submitted by Sciegen Pharmaceuticals.

StrategyJuly 5, 2026

FDA Grants Approval for Valsartan ANDA218897 by Laurus

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Valsartan submitted by Laurus.

RegulatoryJune 21, 2026

FDA Grants AP Status for Losartan Potassium ANDA090382 by Strides Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Strides Pharma.

StrategyJune 21, 2026

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA

Lupin Ltd. has received an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium.

ClinicalJune 20, 2026

Limited FDA-approved Antihypertensive Therapies for Pediatric Patients Highlighted

There is a significant unmet medical need for antihypertensive therapies in pediatric patients, especially those under six years old.

RegulatoryJune 7, 2026

FDA Approval Status Update for Losartan Potassium by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Micro Labs.

Companies

Assets

Recent signals(17)

Teva's Losartan Potassium Supplement Application Receives Standard Review Status

FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094

FDA Accepts Supplemental Application for AVAPRO by Sanofi

FDA Accepts Supplemental NDA for AVAPRO by Sanofi

FDA Approval Status for Valsartan and Hydrochlorothiazide by Sciegen Pharms

FDA Grants Approval for Valsartan ANDA218897 by Laurus

FDA Approval Process for Olmesartan Medoxomil and Hydrochlorothiazide by Micro Labs

FDA Grants Approval for Irbesartan ANDA077205 by Chartwell Molecular

FDA Grants AP Status for Irbesartan ANDA206194 by Hisun Pharm

Crescent Pharma recalls Ramipril 2.5mg due to packaging error

FDA Grants AP Status for Olmesartan Medoxomil and Hydrochlorothiazide ANDA207037

FDA Approves ANDA204687 for Valsartan and Hydrochlorothiazide

FDA Grants Approval for Valsartan ANDA218897 by Laurus

FDA Grants AP Status for Losartan Potassium ANDA090382 by Strides Pharma

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA

Limited FDA-approved Antihypertensive Therapies for Pediatric Patients Highlighted

FDA Approval Status Update for Losartan Potassium by Micro Labs

Upcoming catalysts

Indications

Get signals before the market moves